Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Neurosurgical review
- Publicado em
- 20 ago 2024
- Citações
- 5
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis
Mohammad Amin Habibi, Niloufar Shad, Mohammad Sina Mirjani, Sara Fasihi, Sara Sadeghi, Shaghayegh Karami, Muhammad Hussain Ahmadvand, Pouria Delbari, Amir Hossein Zare, Amir Hessam Zare et al.
Descritores MeSH
- Bevacizumab
- Temozolomide
- Brain Neoplasms
- Glioblastoma
- Chemoradiotherapy
- Humans
- Progression-Free Survival
- Antineoplastic Agents, Alkylating
Veja também
Estudos relacionados
- Short-course radiotherapy with or without temozolomide in elderly patients with newly diagnosed glioblastoma: a time-to-event meta-analysis of overall and progression-free survival
- A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme
- Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma
- The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis